Kiniksa Pharmaceuticals Ltd (KNSA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $7.57B
Last updated: Nov 17, 2026 at 11:06 AM ET
Kiniksa Pharmaceuticals Ltd (KNSA) Financials: Revenue, Profit and Cash Flow
Kiniksa Pharmaceuticals reported revenue of $677.56M for the fiscal year ended Dec 31, 2025, up 60.1% from the year before. That year, net income was $59.01M with a net margin of 8.7%, operating cash flow was $137.99M and free cash flow was $136.42M. The quarter ended Sep 30, 2026 had revenue of $285.97M and net income of $47.34M.
Revenue and Margins
The operating margin was 11.4% in the fiscal year ended Dec 2025, the highest of the 4 years shown with an operating margin.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $677.56M | +60.1% | 54.7% | 11.4% | 8.7% |
| Dec 2024 | $423.24M | +56.6% | 55.3% | -10.8% | -10.2% |
| Dec 2023 | $270.26M | +22.7% | 66.7% | -9.3% | 5.2% |
| Dec 2022 | $220.18M | +471.2% | 78.7% | 4.4% | 83.3% |
| Dec 2021 | $38.54M | N/A | 74.2% | -406.4% | -409.7% |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income rose 156.9% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $677.56M | $423.24M | $270.26M | $220.18M | $38.54M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $307.22M | $189.22M | $89.93M | $46.97M | $9.94M | $0 | $0 | $0 | $0 | $22.00K |
| Gross profit | $370.35M | $234.02M | $180.33M | $173.21M | $28.61M | $0 | $0 | $0 | $0 | -$22.00K |
| Research and development | $96.85M | $111.62M | $76.10M | $65.49M | $99.30M | $112.04M | $135.00M | $86.60M | $56.36M | $17.44M |
| Operating income | $77.22M | -$45.62M | -$25.20M | $9.77M | -$156.64M | -$157.36M | -$169.96M | -$108.16M | -$65.40M | -$24.00M |
| Net income | $59.01M | -$43.19M | $14.08M | $183.36M | -$157.92M | -$161.38M | -$161.87M | -$103.23M | -$64.87M | -$23.97M |
| EBITDA | $89.51M | -$34.02M | -$15.38M | $13.35M | -$153.52M | -$153.70M | N/A | N/A | -$65.37M | -$23.98M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $285.97M | $243.60M | $214.27M | $202.13M | $180.85M | $156.80M | $137.78M | $122.54M | $112.21M | $108.63M | $79.86M | $83.39M |
| Gross profit | $152.38M | $131.96M | $117.89M | $111.15M | $97.29M | $85.78M | $76.13M | $56.45M | $62.80M | $66.30M | $48.47M | $56.87M |
| Operating income | $54.24M | $27.19M | $29.27M | $19.77M | $24.02M | $20.16M | $13.27M | -$19.30M | -$9.66M | -$117.00K | -$16.54M | $81.00K |
| Net income | $47.34M | $25.43M | $22.59M | $14.20M | $18.43M | $17.83M | $8.54M | -$8.89M | -$12.69M | -$3.91M | -$17.70M | $25.24M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $2.99M by $162.61M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $763.63M | $580.55M | $526.32M | $459.67M | $232.80M | $349.46M | $254.53M | $321.96M | $47.49M | $56.47M |
| Current assets | $527.18M | $331.80M | $276.30M | $243.06M | $196.45M | $333.25M | $241.63M | $313.75M | $47.10M | $56.33M |
| Cash and equivalents | $165.60M | $183.58M | $107.95M | $122.72M | $122.47M | $114.04M | $46.93M | $71.98M | $45.55M | $55.97M |
| Total liabilities | $196.03M | $142.12M | $87.48M | $63.52M | $47.76M | $37.53M | $29.11M | $42.70M | $17.43M | $82.20M |
| Short-term debt | $2.99M | $1.99M | $2.25M | $3.30M | $3.38M | $2.11M | $1.70M | N/A | N/A | N/A |
| Shareholder equity | $567.61M | $438.44M | $438.84M | $396.15M | $185.04M | $311.94M | $225.42M | $279.27M | -$89.71M | -$25.73M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $983.24M | $896.11M | $825.28M | $763.63M | $712.33M | $661.15M | $599.33M | $580.55M | $555.30M | $542.43M | $519.67M | $526.32M |
| Total liabilities | $273.05M | $241.96M | $219.59M | $196.03M | $176.95M | $166.14M | $141.84M | $142.12M | $118.29M | $107.33M | $87.78M | $87.48M |
| Cash and equivalents | $81.66M | $175.68M | $189.95M | $165.60M | $174.86M | $192.04M | $157.13M | $183.58M | $97.38M | $99.27M | $141.08M | $107.95M |
| Shareholder equity | $710.19M | $654.15M | $605.69M | $567.61M | $535.38M | $495.01M | $457.49M | $438.44M | $437.01M | $435.10M | $431.89M | $438.84M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 98.9% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $137.99M | $25.69M | $13.30M | $5.81M | -$126.30M | -$136.53M | -$158.37M | -$81.01M | -$50.22M | -$21.87M |
| Capital expenditures | $1.57M | $430.00K | $130.00K | $105.00K | $415.00K | $283.00K | $3.20M | $5.29M | $69.00K | $3.00K |
| Free cash flow | $136.42M | $25.26M | $13.17M | $5.70M | -$126.71M | -$136.81M | -$161.57M | -$86.30M | -$50.29M | -$21.87M |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | $1.14M | $118.00K | $3.66M | $0 | N/A |
| Investing cash flow | -$188.99M | $37.67M | -$29.56M | -$8.08M | $128.63M | -$23.44M | $49.21M | -$239.20M | -$69.00K | -$3.00K |
| Financing cash flow | $33.02M | $12.27M | $1.50M | $2.52M | $5.88M | $227.09M | $84.11M | $346.74M | $39.87M | $42.51M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $47.55M | $47.20M | $50.20M | $53.89M | $33.68M | $28.09M | $22.32M | $18.77M | -$2.24M | $5.17M | $3.99M | $4.33M |
| Capital expenditures | $180.00K | $663.00K | $161.00K | $633.00K | $671.00K | $165.00K | $99.00K | $346.00K | $0 | $0 | $84.00K | $56.00K |
| Free cash flow | $47.37M | $46.53M | $50.04M | $53.26M | $33.01M | $27.93M | $22.23M | $18.42M | -$2.24M | $5.17M | $3.90M | $4.27M |
Frequently Asked Questions About KNSA
What is Kiniksa Pharmaceuticals' annual revenue?
Kiniksa Pharmaceuticals reported revenue of $677.56M for the fiscal year ended Dec 31, 2025.
How fast is Kiniksa Pharmaceuticals' revenue growing?
Revenue was up 60.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 45.5%.
Is Kiniksa Pharmaceuticals profitable?
Yes. Kiniksa Pharmaceuticals reported net income of $59.01M for the fiscal year ended Dec 31, 2025, with a net margin of 8.7%.
How much free cash flow does KNSA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $137.99M minus capital expenditures of $1.57M produced free cash flow of $136.42M.
How much debt does Kiniksa Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $2.99M and cash and equivalents of $165.60M.
KNSA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts